Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | THRA | P10827 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.45 |
| ▸ | KLK1 | P06870 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 5/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157229 | 0.90 | SMN1; SMN2 (0.52) | SMN1; SMN2MAPK1THRATHRBKLKB1 | |
| SCHEMBL2156996 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2MAPK1THRATHRBMAPT | |
| SCHEMBL2156788 | 0.82 | DRD4 (0.50) | SMN1; SMN2MAPK1MAPTKMT2ATP53 | |
| SCHEMBL2156991 | 0.80 | PLA2G2A (0.42) | SMN1; SMN2MAPK1MAPTMEN1KMT2A | |
| SCHEMBL2156852 | 0.78 | LMNA (0.48) | SMN1; SMN2MAPK1THRATHRBMAPT | |
| SCHEMBL19062528 | 0.78 | CYP19A1 (0.69) | SMN1; SMN2MAPK1MAPTMEN1KMT2A | |
| SCHEMBL8502523 | 0.78 | PLA2G2A (0.48) | SMN1; SMN2MAPK1THRATHRBKLKB1 | |
| SCHEMBL2156892 | 0.76 | PLA2G2A (0.52) | SMN1; SMN2MAPK1KLKB1KLK1MAPT | |
| SCHEMBL3919134 | 0.75 | THRB (0.52) | SMN1; SMN2MAPK1THRATHRBMAPT | |
| SCHEMBL14529788 | 0.75 | SMN1; SMN2 (0.65) | SMN1; SMN2MAPK1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2341045-A1 | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid (acyloxy)alkyl or ((alkoxycarbonyl)oxy)alkyl ester as SPLA2 inhibitor | Eli Lilly and Company (US) | 2011-07-06 | — | — | EP | disclosed |
| EP-1950200-A1 | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor | ELI LILLY AND COMPANY (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1039911-B1 | MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA 2 INHIBITORS | LILLY CO ELI (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | LOH ANDREW (US) | 2004-06-10 | — | — | US | disclosed |
| EP-1303262-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6433001-B1 | SEPTIC SHOCK, ALLERGIC RHINITIS, RHEUMATIC ARTHRITIS, ADULT RESPIRATORY DISTRESS SYNDROME, BRONCHIAL ASTHMA, TRAUMA, AND PANCREATITIS TREATMENT | ELI LILLY AND COMPANY | 2002-08-13 | — | — | US | disclosed |
| EP-1039911-A4 | MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA 2 INHIBITORS | LILLY CO ELI (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-1030661-A4 | N,N-DIETHYLGLYCOLAMIDO ESTER PRODRUGS OF INDOLE sPLA 2? INHIBITORS | LILLY CO ELI (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-0675110-B1 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | LILLY CO ELI (US) | 2002-07-10 | — | — | EP | disclosed |
| EP-1197484-A2 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2002-04-17 | — | — | EP | disclosed |
| US-5972988-A | A 1H-INDOLE-3-GLYOXYLAMIDE COMPOUND FOR TREATING RESPIRATORY SYSTEM DISORDER | ELI LILLY AND COMPANY (US) | 1999-10-26 | — | — | US | disclosed |
| US-5919810-A | SEPTIC SHOCK | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5919943-A | INHIBITION OF SPLA2 | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| WO-1999021545-A1 | ISOPROPYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1999-05-06 | — | — | WO | disclosed |
| WO-1999021546-A1 | N,N-DIETHYLGLYCOLAMIDO ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1999-05-06 | — | — | WO | disclosed |
| WO-1999021559-A1 | MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1999-05-06 | — | — | WO | disclosed |
| WO-1998042343-A1 | METHOD FOR TREATMENT OF CHRONIC BRONCHITIS | ELI LILLY AND COMPANY (US) | 1998-10-01 | — | — | WO | disclosed |
| US-5733923-A | SECRETORY PANCREATIC PHOSPHOLIPASE A2 | ELI LILLY AND COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| US-5654326-A | SEPTIC SHOCK; HUMAN NONPANCREATIC SECRETORY PHOSPHOLIPASE | ELI LILLY AND COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0675110-A1 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | PLA2G12A, PLA2G2E, PLA2G3 | SMN1; SMN2 674/4885MAPK1 3651/4885THRA 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.